Johnson & Johnson is buying Abiomed for $16.6 billion, or $380 per share. Company develops and sells medical devices to help or replace pumping function of the failing heart, such as Abiomed and Impella. Abiomed shareholders will also be entitled to another $35.00 per share if certain commercial and clinical milestones are met. Transaction is expected to close in the first quarter of 2023.